ExeGi Pharma Positive Topline Results in EXE-346 PROF Phase 1b Study
Hand-out
Press Releases
December 17, 2024

ExeGi Pharma Positive Topline Results in EXE-346 PROF Phase 1b Study

PROF study demonstrates safety of EXE-346 drug product in pouch anastomosis patients at 3,000 billion live probiotic consumption per day for four weeksExcessive bowel movement (BM) frequency was reduced at

bradford

The Bradford Era

More by this Author
Local & Social